Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02788474 · ClinicalTrials.gov registry record · Phase 4
Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 347
- Enrollment target
NCT02788474 is a Phase 4 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 347 participants.
The verdict
NCT02788474, a Phase 4 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 347 participants
- Enrollment target
Study Summary
Identifying biomarkers to predict the clinical course and benefits of therapy early in the course of the disease remains one of the most urgent and relevant challenges to improve overall patient management, to prevent treatment delay or overtreatment. This study is conducted to examine the effect of nintedanib treatment on change in biomarkers indicative of extracellular matrix turnover which have been shown recently to correlate with disease progression. This study further aims to confirm the association of biomarker course during the first three months of treatment and disease progression.
Interventions
- DRUG placebo
- DRUG nintedanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 347 participants |
| Start Date | 2016-06-09 |
| Est. Completion | 2018-06-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02788474
The ClinicalTrials.gov registry entry for NCT02788474 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 347 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02788474 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02788474 about?
NCT02788474 is a clinical study titled "Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment". Identifying biomarkers to predict the clinical course and benefits of therapy early in the course of the disease remains one of the most urgent and relevant challenges to improve overall patient management, to prevent treatment delay or overtreatment. This study is conducted to examine the effect of...
What is the current status of trial NCT02788474?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 347 participants. The study started on 2016-06-09. Estimated completion is 2018-06-08.
What interventions are being tested in trial NCT02788474?
The interventions under investigation include: placebo (DRUG), nintedanib (DRUG).
Who is sponsoring clinical trial NCT02788474?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.